VISTIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vistide, and what generic alternatives are available?
Vistide is a drug marketed by Gilead Sciences Inc and is included in one NDA.
The generic ingredient in VISTIDE is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vistide
A generic version of VISTIDE was approved as cidofovir by MYLAN INSTITUTIONAL on June 27th, 2012.
Summary for VISTIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Clinical Trials: | 11 |
Patent Applications: | 5,024 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in VISTIDE? | VISTIDE excipients list |
DailyMed Link: | VISTIDE at DailyMed |
Recent Clinical Trials for VISTIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centro de Investigación en. Enfermedades Infecciosas, Mexico | Phase 2 |
M.D. Anderson Cancer Center | Phase 1 |
Gilead Sciences | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for VISTIDE
US Patents and Regulatory Information for VISTIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VISTIDE | cidofovir | INJECTABLE;INJECTION | 020638-001 | Jun 26, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISTIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VISTIDE | cidofovir | INJECTABLE;INJECTION | 020638-001 | Jun 26, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for VISTIDE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Gilead Sciences International Limited | Vistide | cidofovir | EMEA/H/C/000121 Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable., |
Withdrawn | no | no | no | 1997-04-23 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VISTIDE
See the table below for patents covering VISTIDE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 8705283 | ⤷ Try a Trial | |
Australia | 7575987 | ⤷ Try a Trial | |
Ireland | 60117 | N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | ⤷ Try a Trial |
Japan | H0822866 | ⤷ Try a Trial | |
Portugal | 85354 | PROCESSO DE PREPARACAO DE DERIVADOS N-FOSFONILMETOXIALQUILO DE BASES PIRIMIDINA E PURINA E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISTIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0253412 | C970036 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: CIDOFOVIR,DESGEWENST IN DE VORM VAN EEN ZOUT MET AMMONIA,EEN ALKALIMETAAL OF EEN AMINE; REGISTRATION NO/DATE: EU/1/97/037/001 19970423 |
0253412 | 97C0105 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: EU/1/97/037/001 19970423 |
0253412 | 63/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: K (97) 1176 19970423 |
0253412 | SPC/GB97/083 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CIDOFOVIR; REGISTERED: UK EU/1/97/037/001 19970423 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |